Table 3.

Plasma immune mediators

Variable (median [IQR])	Non-HR HPV (n=76)	HR HPV (n=40)	HPV16 (n=8)	p-value
IL-2 (pg/mL)	0.57 [0.26–0.76]	0.57 [0.15–0.99]	0.87 [0.31–1.34]	0.55
IL-6 (pg/mL)	1.61 [0.67–6.32]	1.67 [0.87–3.97]	3.2 [1.66–5.74]	0.48
MIP-1β (pg/mL)	24.4 [14.5–42.4]	21.0 [16.6–35.4]	21.9 [18.3–34.5]	0.93
IL-8 (pg/mL)	17.9 [7.9–80.5]	15.5[8.3–185.4]	12.9 [5.9–72.0]	0.69
TNF (pg/mL)	6.63 [4.18–9.91]	6.3 [4.86–10.47]	7.17 [5.12–13.68]	0.57
IFN-γ (pg/mL)	2.49 [1.37–4.27]	1.83 [0.49–3.33]	2.21 [1.98–4.09]	0.12
IL-1α, n (%)	11 (14.5%)	3 (7.5%)	0 (0%)	0.45
IL-1β, n (%)	33 (43.4%)	15 (37.5%)	4 (50%)	0.73
IFN-α2, n (%)	44 (57.9%)	15 (37.5%)	4 (50%)	0.12
IL-1ra, n (%)	20 (32.8%)	9 (28.1%)	1 (20%)	0.96
RANTES, n (%)	43 (56.6%)	27 (67.5%)	6 (75%)	0.37
MIP-1α, n (%)	54 (71.1%)	22 (55%)	4 (50%)	0.14
IL-17, n (%)	51 (67.1%)	27 (67.5%)	7 (87.5%)	0.49

Plasma IL-1α, IL-1β, IFN-α2, IL-1ra, RANTES, MIP-1α, and IL-17 with > 25% of samples below the lower limit of detection (LLOD) were dichotomized at the LLOD and the n (%) of participants with detectable levels are shown.